Table 3.
Logistic Regression Analyses Assessing Characteristics Associated With Non-SVR Among Individuals Treated With SOF/VEL, BC Hepatitis Testers Cohort, 2016–2018
| Overall | GT1 | GT3 | |
|---|---|---|---|
| aOR (95% CI) | aOR (95% CI) | aOR (95% CI) | |
| Age (vs >60 y), y | |||
| <50 | 1.58 (1.00–2.48) | 1.23 (0.60–2.56) | 1.82 (0.90–3.68) |
| 50–60 | 0.64 (0.41–1.01) | 0.53 (0.26–1.12) | 0.88 (0.45–1.72) |
| Sex (male vs female) | 1.41 (0.98–2.02) | 1.79 (0.95–3.35) | 1.49 (0.86–2.59) |
| HCV treatment experience (yes vs no) | 1.36 (0.83–2.24) | 1.14 (0.46–2.8) | 1.73 (0.89–3.36) |
| Cirrhosis (yes vs no) | 1.21 (0.52–2.80) | 2.64 (0.66–10.59) | 0.66 (0.19–2.34) |
| History of injecting drugs (yes vs no) | 2.35 (1.51–3.66) | 3.82 (1.8–8.12) | 2.32 (1.24–4.36) |
| OST (vs none) | |||
| Recent | 1.08 (0.70–1.66) | 1.69 (0.85–3.35) | 0.52 (0.27–1.01) |
| Past | 1.36 (0.83–2.24) | 0.77 (0.21–2.77) | 0.23 (0.05–1.02) |
| Problematic alcohol use (yes vs no) | 0.74 (0.5–1.09) | 0.72 (0.39–1.34) | 0.61 (0.33–1.12) |
| HIV (yes vs no) | 1.67 (1.02–2.75) | 2.39 (1.13–5.04) | 1.06 (0.48–2.35) |
| HBV (yes vs no) | 0.74 (0.37–1.49) | 0.76 (0.26–2.22) | 1.16 (0.43–3.14) |
| Genotype (vs GT1) | |||
| GT2 | 0.78 (0.46–1.35) | NA | NA |
| GT3 | 1.00 (0.69–1.44) | NA | NA |
| GT4-6 | 0.64 (0.25–1.66) | NA | NA |
| SOF/VEL+RBV (vs SOF/VEL) | 1.93 (1.19–3.13) | 0.97 (0.38–2.53) | 3.10 (1.67–5.76) |
Bold formatting indicates P < .05. When treatment variable (SOF/VEL vs SOF/VEL+RBV) was removed from the model, “HCV treatment experience” was significant for the GT3 model (aOR, 2.03; 95% CI, 1.06–3.89). GT2 is not shown.
Abbreviations: aOR, adjusted odds ratio; BC, British Columbia; CI, confidence interval; GT, genotype; HBV, hepatitis B virus; HCV, hepatitis C virus; NA, not applicable; OST, opioid substitution therapy; RBV, ribavirin; SOF, sofosbuvir; SVR, sustained virologic response; VEL, velpatasvir.